Select Page

Anti-Human VEGF (Bevacizumab) – HRP – 100 µg

100 μg



ApplicationELISA, FC
ConjugateHorseradish Peroxidase (HRPO)
IsotypeHuman IgG1κ
ImmunogenRecombinant human VEGF.
Species ReactivityHuman
FormulationThis HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Research AreaCancer, Immunology
Description/BackgroundBevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.
Storage TemperatureThis horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
ProtocolsELISA, FC
Clone NumberA4.6.1
Concentration0.5 mg/ml
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
100 μg